Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Uni-Bio to Begin Phase III Trial of Diabetes Drug

publication date: Jul 9, 2009

Uni-Bio Science Group Limited, a Hong Kong listed and headquartered company whose operations are largely in mainland China, will soon begin enrolling diabetes patients in its Phase III clinical trial for Recombinant Exendin-4 (rExendin-4 also known as exenatide). rExendin-4 is an incretin mimetic. Similar to the human incretin hormone glucagon-like peptide-1 (GLP-1), rExendin kicks in when blood sugar levels are high, such as following meals, to bring blood glucose levels back to normal levels. More details...

Stock Symbol: (HKEX: 0690)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here